<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: We examined the involvement of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) accompanied by peripheral cytopenias despite normo-hypercellular bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Bone marrow smears from 31 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) and five <z:mpath ids='MPATH_458'>normal</z:mpath> controls were stained using the in situ end labeling (ISEL) method </plain></SENT>
<SENT sid="2" pm="."><plain>Next, the inhibitory effects of a caspase-3 inhibitor, <z:chebi fb="0" ids="50664">matrix metalloproteinase inhibitor</z:chebi> (<z:chebi fb="4" ids="50664">MMPI</z:chebi>), anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-alpha or anti-Fas antibody upon the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction in overnight cultures of bone marrow cells from the patients were examined </plain></SENT>
<SENT sid="3" pm="."><plain>Further, TNF-alpha, transforming growth factor (TGF)-beta and soluble Fas ligand (sFasL) concentrations in culture supernatants of the cells were assessed by enzyme-linked immunosorbent assay (ELISA) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The incidence of ISEL-positive cells among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients was significantly higher than in <z:mpath ids='MPATH_458'>normal</z:mpath> controls (50.8 +/- 14.0% vs. 11.3 +/- 2.4%; P &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>A caspase-3 inhibitor reduced significantly the ISEL-positive rates (32.6 +/- 15.2% vs. 50.2 +/- 16.5%; P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>Anti-TNF-alpha or anti-Fas antibody reduced the ISEL-positive rates significantly (28.2 +/- 6.0%, 29.2 +/- 5.8%, vs. 44.2 +/- 3.4%, P &lt; 0.001, P = 0.001, respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>KB-R7785 also significantly decreased the ISEL-positive rates (18.0 +/- 9.3% vs. 43.6 +/- 14.0%; P &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>The concentration of TNF-alpha was significantly reduced by KB-R7785 (P &lt; 0.05), whereas that of TGF-beta was not </plain></SENT>
<SENT sid="9" pm="."><plain>Concentration of sFasL was under detectable level in the present assay system </plain></SENT>
<SENT sid="10" pm="."><plain>The derivatives of KB-R7785 that can be administrated orally showed inhibitory effect on <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction as well </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These findings suggest that <z:chebi fb="4" ids="50664">MMPIs</z:chebi> inhibits the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow cells via the inhibition of TNF-alpha and probably sFasL secretion, and that <z:chebi fb="4" ids="50664">MMPIs</z:chebi> can be used to control the abnormal induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>